Newsbenzinga
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
· Published
Article summary
Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and reinforced its regulatory outlook.
An excerpt from the original article.
Comments —
Loading comments…